View Filing Data

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2009	Dec. 31, 2008
Current assets
Cash and cash equivalents	$ 0	$ 0
Receivables, less allowance for doubtful accounts of $9,828 and $11,629 at September 30, 2009 and December 31, 2008, respectively	147,326	158,649
Inventory	47,833	45,227
Prepaid expenses and other current assets	3,866	2,766
Total current assets	199,025	206,642
Property and equipment, net	15,674	14,748
Other assets	983	1,069
Goodwill	24,498	24,498
Total assets	240,180	246,957
Current liabilities
Line of credit	39,584	50,411
Accounts payable	62,909	76,936
Claims payable	4,228	5,230
Amounts due to plan sponsors	5,951	5,646
Accrued expenses and other current liabilities	10,200	9,575
Total current liabilities	122,872	147,798
Deferred taxes	1,095	533
Income taxes payable	3,512	3,089
Total liabilities	127,479	151,420
Stockholders' equity
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $.0001 par value; 75,000,000 shares authorized; shares issued: 42,349,728, and 41,622,629, respectively; shares outstanding; 39,272,399 and 38,691,356, respectively	4	4
Treasury stock, shares at cost: 2,653,007 and 2,624,186, respectively	(10,366)	(10,288)
Additional paid-in capital	252,274	248,441
Accumulated deficit	(129,211)	(142,620)
Total stockholders' equity	112,701	95,537
Total liabilities and stockholders' equity	$ 240,180	$ 246,957

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2009

NOTE 3 – EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted income per common share (in thousands, except for per share amounts):

lt;td colspan="5" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"September 30,/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="5" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"September 30,/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" vali gn="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style=" DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Numerator:/font/div /td td align="left" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Net income/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,747/font/td td nowrap= "nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,410/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10p t; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"13,409/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,552/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADD ING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Denominator - Basic:/font/div /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FON T-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim es new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; t;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Weighted average number of common shares outstanding/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double ; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,961/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,403/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/ font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,807/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: righ t"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,359/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Basic income per common share/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1% " style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"0.15/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman "0.04/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"0.35/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIG N: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"0.07/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Denominator - Diluted:/font/div /td td align="left" valign="bottom" width="1%"fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FO NT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" ;#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Weighted average number of common shares outstanding/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,961/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,403/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,807/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" w idth="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,359/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Common share equivalents of outstanding stock options and restricted awards/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ti mes new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,223/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"531/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"538/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; ;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"828/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total diluted shares outstanding/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"40,184/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" ;#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,934/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"39,345/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"39,187/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/fo nt/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Diluted income per common share/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; F ONT-FAMILY: times new roman"0.14/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"0.04/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"0.34/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"0.07/font t;/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2009 were 2,995,497 and 4,530,529 shares, respectively, and for the three and nine months ended September 30, 2008 were 4,716,212 and 3,839,179 shares, respectively, all of which are issuable upon the exercise of outstanding stock options.#160;#160;The inclusion of those shares would have been anti-dilutive as the exercise price of these shares exceeded market value./font/divbr //div

Three Months Ended

< /font>

Nine Months Ended

STOCK BASED COMPENSATION PLANS	9 Months Ended
STOCK BASED COMPENSATION PLANS	Sep. 30, 2009
Stock-Based Compensation Plans [Abstract]
STOCK-BASED COMPENSATION PLANS	br / div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE 4 #8211; STOCK-BASED COMPENSATION PLANS/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under the Company#8217;s 2008 Equity Incentive Plan (the #8220;2008 Plan#8221;) the Company may issue, among other things, incentive stock options (#8220;ISOs#8221;), non-qualified stock options (#8220;NQSOs#8221;), stock appreciation rights, restricted stock, and performance units to employees and directors. #160;#160;Under the 2008 Plan, 3,580,000 shares were authorized for issuance (subject to adjustment for grants made under the Company#8217;s 2001 Incentive Stock Plan (the #8220;2001 Plan#8221;) after January 1, 2008, as well as for forfeitures, expirations or awards that under the 2001 Plan otherwise settled in cash after the adoption thereof).#160;#160;As of September 30, 2009, 200,670 shares remained available for grant under the 2008 Plan.#160;#160;Upon effectiveness of the 2008 Plan in April 2008, the Company ceased making grants under the 2001 Plan.#160;#160;The 2008 Plan and the 2001 Plan are administered by the Company#8217;s Management Development and Compensation Committee (the #8220;Compensation Committee#8221;), a standing committee of the Board of Directors (the #8220;Board#8221;)./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY : block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under the terms of the 2008 Plan and the 2001 Plan, plan participants may use shares to cover tax withholding on income earned as a result of appreciation of equity-based instruments upon exercise, vesting and/or lapsing of restrictions thereon.#160;#160;Upon the exercise of stock options and the vesting of other equity awards granted under the Plans, participants will generally have taxable income subject to statutory withholding requirements.#160;#160;The number of shares that may be issued to participants upon the exercise of stock options and the vesting of equity awards may be reduced by the number of shares having a market value equal to the amount of tax required to be withheld by the Company to satisfy Federal, state and local tax obligations as a result of such exercise or vesting./font/div ; div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Stock Options/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Options granted under the Plan: (a) typically vest over a three-year period and, in certain instances, fully vest upon a change in control of the Company, (b) have an exercise price that may not be less than 100% of its fair market value on the date of grant (110% for ISOs granted to a stockholder who holds more than 10% of the outstanding stock of the Company), and (c) are generally exerci sable for ten years (five years for ISOs granted to a stockholder holding more than 10% of the outstanding stock of the Company) after the date of grant, subject to earlier termination in certain circumstances./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company recognized compensation expense related to stock options of $0.6 million and $0.4 million for the three months ended September 30, 2009 and 2008, respectively, and $1.5 million and $1.7 million for the nine months ended September 30, 2009 and 2008, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style= "DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The fair value of each stock option award on the date of the grant was calculated using a binomial option-pricing model.#160;#160;Option expense is amortized on a straight-line basis over the requisite service period and was calculated with the following weighted average assumptions:/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;/fontbr /#160;/div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" tr td align="left" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 1 0pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="5" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Three Months Ended/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="5" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Nine Months Ended/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="5" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FO NT-FAMILY: times new roman"September 30,/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="5" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"September 30,/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td align="left" valign="bottom" style="PADDING-B OTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Expected volatility/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"66.0/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right "font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"66.5/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMI LY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"51.2/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Risk-free interest rate/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="b ottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3.55/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2.97/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3.86 /font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"%/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Expected life of options/font/div /td td align="left" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="TEXT-ALIGN: right" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman"5.1 years/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="TEXT-ALIGN: right" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.6 years/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" style="TEXT-ALIGN: right" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5.7 years/font/div /td td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT- INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Dividend rate/font/div /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left" t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMI LY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Fair value of options/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3.37/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1.60/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" ;$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3.50/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"No stock options or other equity-based incentive grants were made during the three months ended September 30, 2008 and as such, no binomial pricing model assumptions for new grants were establishe d./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"At September 30, 2009, there was $3.5 million of unrecognized compensation expense related to unvested option grants. That expense is expected to be recognized over a weighted-average period of 2.0 years./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"#160;/font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT- SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Restricted Stock/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under the 2008 Plan, stock grants subject solely to an employee#8217;s or director#8217;s continued service with the Company will not become fully vested less than (a) three years from the date of grant to employees and, in certain instances, may fully vest upon a change in control of the Company, and (b) one year from the date of grant for directors.#160;#160;Stock grants subject to the achievement of performance conditions will not vest less than one year from the date of grant where the vesting of stock grants is subject to performance measures.#160;#160;Such performance shares may vest af ter one year from grant.#160;#160;No such time restrictions applied to stock grants made under the Company#8217;s prior equity compensation plans./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company recognized compensation expense related to restricted stock awards of $0.3 million and $0.5 million for the three months ended September 30, 2009 and 2008, respectively, and $0.9 million and $1.2 million for the nine months ended September 30, 2009 and 2008, respectively./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10p t; FONT-FAMILY: Times New Roman"As of September 30, 2009, there was $1.0 million of unrecognized compensation expense related to unvested restricted stock awards. That expense is expected to be recognized over a weighted-average period of 1.4 years./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Since the Company records compensation expense for restricted stock awards based on the vesting requirements, which generally includes time elapsed, market conditions and/or performance conditions, the weighted average period over which the expense is recognized may vary from quarter to quarter. Also, future equity-based compensation expense may be greater if additional restricted stock awards are made./font/div div style="DISP LAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Performance Units/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Under the 2008 Plan, the Compensation Committee may grant performance units to key employees. The Compensation Committee will establish the terms and conditions of any performance units granted, including the performance goals, the performance period and the value for each performance unit. If the performance goals are satisfied, the Company would pay the key employee an amount in cash equal to the value of each performance unit at the time of payment. In no event may a key employee receive an amount in excess of $1.0 million with respect to performance units for any given year. To date, no performance units have been granted under the 2008 Plan./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div /div

OPERATING SEGMENTS	9 Months Ended
OPERATING SEGMENTS	Sep. 30, 2009
Operating Segments [Abstract]
OPERATING SEGMENTS	div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE 5 #8211; OPERATING SEGMENTS/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In accordance with ASC 280 font style="DISPLAY: inline; FONT-STYLE: italic"Segment Reporting/font, (#8220;ASC 280#8221;), (formerly SFAS No. 131, font style="DISPLAY: inline; FONT-STYLE: italic"Disclosures about Segments of an Enterprise and Related Information/font (#8220;SFAS 131#8221;)), and based on the nature of the Company p;#8217;s services, the Company has two reportable segments: Specialty Pharmacy Services and Traditional Pharmacy Services.#160;#160;ASC 280 requires an enterprise to report segment information in the same way that management internally organizes its business for assessing performance and making decisions regarding allocation of resources.#160;#160;The Company evaluates the performance of operating segments and allocates resources based on income from operations./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Revenues from Specialty Pharmacy Services and Traditional Pharmacy Services are derived from the Company#8217;s relationships with healthcare payors, including managed care organizations, government funded and/or opera ted programs,#160;#160;third party administrators (#8220;TPAs#8221;) and self-funded employer groups (collectively, #8220;Plan Sponsors#8221;) as well as from our relationship with pharmaceutical manufacturers, patients and physicians./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Specialty Pharmacy Services segment consists of the Company#8217;s specialty pharmacy distribution and therapy management services.#160;#160;Specialty Pharmacy Services distribution occurs locally through community pharmacies, centrally through mail order facilities and through our infusion pharmacies for patients requiring infused medications in the home or infused at a variety of sites including the Company#8217;s a mbulatory infusion sites.#160;#160;All Specialty Pharmacy Services target certain specialty medications that are used to treat patients living with chronic and other complex healthcare conditions./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Traditional Pharmacy Services segment consists mainly of traditional mail order pharmacy fulfillment, and to a lesser extent, prescription discount card programs and integrated pharmacy benefit management services.#160;#160;These Traditional Pharmacy Services are designed to offer Plan Sponsors cost-effective delivery of pharmacy benefit plans including the low cost distribution of mail services for plan members who receive traditional maintenance medications./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In the quarter ended September 30, 2009, the Company renamed the reportable segment formerly known as #8220;PBM Services#8221; to #8220;Traditional Pharmacy Services#8221;.#160;#160;The new title reflects a shift in the nature of the business included in this segment which has become substantially more weighted towards services other than fully funded pharmacy benefit management including traditional mail service pharmacy fulfillment and prescription discount card programs./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Segment Reporting Information/font/div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"(in thousands)/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div align="left" table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" tr td align="left" valign="bottom" width="52%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; ;/font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="6" valign="bottom" width="22%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Three Months Ended/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="6" valign="bottom" wid th="22%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Nine Months Ended/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="6" valign= "bottom" width="22%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"September 30,/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="cent er"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"September 30,/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block ; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008 /font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2009/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inl ine; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2008/font/div /td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align=" left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Results of Operations:/font/div /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times n ew roman"#160;/font/td td align="left" colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/ td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Revenue:/font/div /td td align="left" valign="bottom" width="1%" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 1 0pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" colspan="2" valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td gt; td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"279,006/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"307,135/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left" gt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"828,790/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roma n"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"882,590/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"54,470/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"52,292/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td lt;td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"159,184/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10 pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"152,748/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align ="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"333,476/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" #160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"359,427/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"987,974/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" wi dth="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,035,338/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Income (loss) from operations:/font/div /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="D ISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMI LY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0 pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,007/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td alig n="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"153/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,265/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1,728/font/td ; td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt ; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,654/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: bla ck 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,656/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"10,864/font ;/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"8,090/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPL AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td t d valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,661/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; F ONT-FAMILY: times new roman"2,809/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"16,129/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-B OTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,362/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font t;/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Interest expense, net/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"447/font/td td nowrap="nowr ap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"669/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style=" DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,471/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman "#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,931/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Tax provision/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; F ONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"467/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2p x solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"730/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,249/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inli ne; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,879/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Net income:/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: le ft"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,747/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="botto m" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,410/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"13,409/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,552/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left "font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Capital expenditures:/font/div /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIG N: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"456/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,844/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,018/font/td td nowrap="nowrap" vali gn="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,820/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bott om" width="52%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"137/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"327/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT - -SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"504/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" st yle="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,053/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"593/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" gt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,171/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="r ight" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"4,522/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" amp;#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,873/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Depreciati on Expense:/font/div /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: r ight"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times n ew roman"1,136/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,008/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,003/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISP LAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,870/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BO TTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"220/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"128/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt ; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"593/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"364/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" amp;#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,356/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,136/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,596/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,2 34/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Total Assets/font/div /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-AL IGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F AMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="left" valign="bottom" width="52%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Specialty Pharma cy Services/font/div /td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"172,726/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"269,201/font/td td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F AMILY: times new roman"#160;/font/td /trtr bgcolor="#cceeff" td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;Traditional Pharmacy Services/font/div /td td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT- ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowra p="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"67,454/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FON T-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"67,762/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /trtr bgcolor="white" td align="l eft" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;Total/font/div /td td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" #160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"240,180/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"font style=" DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/td td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"336,963/font/td td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td /tr/table /div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: bl ock; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Certain prior period segment data has been reclassified to conform to the current year#8217;s presentation.#160;#160;These reclassifications had no material impact on previously reported segment data./font/div /div

LINE OF CREDIT	9 Months Ended
LINE OF CREDIT	Sep. 30, 2009
Line of Credit [Abstract]
LINE OF CREDIT	br / div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE 6 #8211; LINE OF CREDIT/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"At September 30, 2009, there was $39.6 million in outstanding borrowings under the Company#8217;s revolving credit facility (the #8220;Facility#8221;) with an affiliate of Healthcare Finance Group, Inc. (#8220;HFG#8221;), as compared to $50.4 million at December 31, 2008.#160;#160;The Facility provides for borrowings of up to $85.0 million, at the Lo ndon Inter-Bank Offered Rate (#8220;LIBOR#8221;) or a pre-determined minimum rate plus the applicable margin and other associated fees, provided that a sufficient level of receivable assets are available as collateral.#160;#160;The term of the Facility runs through November 1, 2010.#160;#160;Under the terms of the Facility, the Company may request to increase the amount available for borrowing up to $100.0 million and convert a portion of any outstanding borrowings from a Revolving Loan into a Term Loan.#160;#160;The borrowing base utilizes receivable balances and proceeds thereof as security under the Facility.#160;#160;At September 30, 2009, the Company had $45.4 million of credit available under the Facility on a borrowing basis of $85.0 million.#160;#160;The weighted average interest rate on the Facility during the quarter ended September 30, 2009 was 4.4% compared to 5.4% for the quarter ended December 31, 2008./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Facility contains various covenants that, among other things, require the Company to maintain certain financial ratios as defined in the agreements governing the Facility.#160;#160;The Company was in compliance with all the covenants contained in the agreements as of September 30, 2009./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2009
Income Taxes [Abstract]
INCOME TAXES	div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"NOTE 7 #8211; INCOME TAXES/font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company uses an estimated annual effective tax rate in determining its quarterly provision for income taxes.#160;#160;The methodology employed is based on the Company#8217;s expected annual income, statutory tax rates and tax strategies utilized in the various jurisdictions in which it operates. /font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Since December 31, 2006, the Company has fully reserved its deferred tax assets as it has concluded that it was more likely than not that its deferred tax assets would not be utilized.#160;#160;The Company continually assesses the necessity of maintaining a valuation allowance for its deferred tax assets.#160;#160;If the Company determines in a future period that it is more likely than not that the deferred tax assets will be utilized based upon application of the criteria required per the accounting literature, the Company will reverse all or part of the valuation allowance for its deferred tax assets./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt" gt;br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"For the quarter ended September 30, 2009, the Company#8217;s provision for income taxes was $0.5 million with an effective tax rate of 7.5%.#160;#160;For the quarter ended September 30, 2008, the Company#8217;s provision for income taxes was $0.7 million with an effective rate of 34.1%.#160;#160;The lower effective tax rate of 7.5% for the current quarter compared to the statutory rate is primarily a result of a reduction in the valuation allowance due to the expected utilization of a portion of the Company#8217;s net operating losses in 2009.#160;#160;The effective tax rate for the quarter ended September 30, 2008 differs from the statutory rate primarily due to amortization of indefinite lived assets./font/div lt;div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"For the nine months ended September 30, 2009, the Company#8217;s provision for income taxes was $1.2 million with an effective tax rate of 8.5%.#160;#160;For the nine months ended September 30, 2008, the Company#8217;s provision for income taxes was $1.9 million with an effective tax rate of 42.4%.#160;#160;The lower effective tax rate of 8.5% for the nine months ended September 30, 2009 compared to the statutory rate is primarily a result of a reduction in the valuation allowance due to the expected utilization of a portion of the net operating losses in 2009.#160;#160;The effective tax rate for the nine months ended September 30, 2008 differs from the statutory rate primarily due to amortizat ion of indefinite lived assets./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company files income tax returns with Federal, state and local jurisdictions.#160;#160;The Company#8217;s uncertain tax positions are related to tax years that remain subject to examination.#160;#160;As of September 30, 2009, U.S. tax returns for the years 2005 through 2008 remain subject to examination by Federal tax authorities.#160;#160;Tax returns for the years 2004 through 2008 remain subject to examination by state and local tax authorities for a majority of the Company#8217;s state and local filings./font/div div style="DISPLAY: block; TEXT-INDENT: 0pt"br //div /div t;

Entity Information - USD ($)	9 Months Ended
Entity Information - USD ($)	Sep. 30, 2009	Dec. 31, 2008
Entity Information [Line Items]
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float		$ 73,200,585
Entity Common Stock, Shares Outstanding	39,316,399

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2009	Sep. 30, 2008	Sep. 30, 2009	Sep. 30, 2008
Statement [Line Items]
Revenue	$ 333,476	$ 359,427	$ 987,974	$ 1,035,338
Cost of revenue	291,980	323,346	872,100	931,159
Gross profit	41,496	36,081	115,874	104,179
Selling, general and administrative expenses	32,402	31,859	94,335	95,031
Bad debt expense	2,433	1,413	5,410	2,786
Income from operations	6,661	2,809	16,129	6,362
Interest expense, net	447	669	1,471	1,931
Income before income taxes	6,214	2,140	14,658	4,431
Tax provision	467	730	1,249	1,879
Net income	$ 5,747	$ 1,410	$ 13,409	$ 2,552
Income per common share
Basic	$ 0.15	$ 0.04	$ 0.35	$ 0.07
Diluted	$ 0.14	$ 0.04	$ 0.34	$ 0.07
Weighted average common shares outstanding
Basic	38,961	38,403	38,807	38,359
Diluted	40,184	38,934	39,345	39,187

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2009	Sep. 30, 2008
Cash flows from operating activities:
Net income	$ 13,409	$ 2,552
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	3,596	4,685
Change in deferred income tax	562	1,440
Compensation under stock-based compensation plans	2,385	2,859
Bad debt expense	5,410	2,786
Changes in assets and liabilities
Receivables, net	5,913	(37,351)
Inventory	(2,606)	(2,557)
Prepaid expenses and other assets	(1,014)	(2,116)
Accounts payable	(14,027)	13,829
Claims payable	(1,002)	879
Amounts due to plan sponsors	305	1,237
Accrued expenses and other liabilities	1,048	(3,629)
Net cash provided by (used in) operating activities	13,979	(15,386)
Cash flows from investing activities:
Purchases of property and equipment, net of disposals	(4,522)	(5,873)
Net cash used in investing activities	(4,522)	(5,873)
Cash flows from financing activities:
Borrowings on line of credit	997,920	1,042,246
Repayments on line of credit	(1,008,747)	(1,021,001)
Surrender of stock to satisfy minimum tax withholding	(78)	(262)
Net proceeds from exercise of employee stock compensation plans	1,448	276
Net cash (used in) provided by financing activities	(9,457)	21,259
Net change in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	1,432	3,092
Cash paid during the period for income taxes	$ 741	$ 236

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2009
Basis of Presentation [Abstract]
BASIS OF PRESENTATION	NOTE 1 – BASIS OF PRESENTATION These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and subsid iaries (the “Company”) for the year ended December 31, 2008 (the “Form 10-K”) filed with the U.S. Securities and Exchange Commission on March 5, 2009. These unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished in these unaudited consolidated financial statements includes normal recurring adjustments and reflects all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three and nine months ended September 30, 2009 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2009. The accounting policies followed for interim financial reporting are similar to those disclosed in Note 2 of Notes to Consolidated Financial Statements included in the Form 10-K. Certain prior period amounts have been reclassified to conform to the current year presentation. Such reclassifications have no material effect on the Company’s previously reported consolidated financial position, results of operations or cash flows. The Company has evaluated events that occurred during the period subsequent to the balance sheet date through November 2, 2009, which represents the filing date of this Form 10-Q. As of November 2, 2009, there were no subsequent events that require recognition or disclosure in the financial statements.

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Sep. 30, 2009
Recent Accounting Pronouncements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS In June 2009, FASB issued Accounting Standards Update No. 2009-01, Generally Accepted Accounting Principles (“ASC Topic 105”) which established the FASB ASC as t he official single source of authoritative U.S. generally accepted accounting principles (“GAAP”). All previously existing accounting standards were superseded at that date. All other accounting guidance not included in the Codification will be considered non-authoritative. The Codification also includes relevant SEC guidance organized using the same topical structure in separate sections within the Codification. Following the Codification, the Board has stated that it will not issue new standards in the form of Statements, FASB Staff Positions or Emerging Issues Task Force Abstracts. Instead, it will issue Ac counting Standards Updates (“ASU”) that will serve to update the Codification, provide background information about the guidance and provide the basis for conclusions on the changes to the Codification. The Codification is not intended to change GAAP, but will change the way GAAP is organized and presented. The Codification is effective for the Company’s third quarter 2009 financial statements and the principal impact is limited to disclosures as all future references to authoritative accounting literature will be referenced in accordance with the Codification. In order to ease the transition to the Codification, the Company is providing the Codification cross-reference alongside the references to the standards issued and adopted prior to the adoption of the Codification.

PARENTHETICAL DATA TO CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2009	Dec. 31, 2008
Current assets
Receivables, less allowance for doubtful accounts	$ 9,828,000	$ 11,629,000
Stockholders' equity
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	42,349,728	41,622,629
Common stock, shares outstanding	39,272,399	38,691,356
Treasury stock, shares at cost	2,653,007	2,624,186